SCHEMBL1380130

SCHEMBL1380130

Cc1nc(C(=O)N2CCN(c3cccc(C(N)=O)c3)CC2)c(-c2ccccc2)[nH]1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP2 O75604 3/20 0.47
MAPK1 P28482 2/20 0.47
TSHR P16473 2/20 0.47
MAPT P10636 2/20 0.47
LMNA P02545 1/20 0.47
MGLL Q99685 1/20 0.46
PARP14 Q460N5 2/20 0.46
PARP10 Q53GL7 1/20 0.46
PDE3B Q13370 1/20 0.46
PDE3A Q14432 1/20 0.46
CHEK2 O96017 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
CYP1A2 P05177 2/20 0.44
CYP3A4 P08684 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
HIF1A Q16665 1/20 0.44
MEN1 O00255 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1384991 0.84 PHGDH (0.46) MGLLL3MBTL1SLC6A7TACR3
SCHEMBL5761570 0.78 USP2 (0.52) USP2MAPK1TSHRMAPTLMNA
SCHEMBL1385439 0.76 USP2 (0.48) USP2MAPK1TSHRMAPTLMNA
SCHEMBL1384633 0.76 USP2 (0.47) USP2MAPK1TSHRMAPTLMNA
SCHEMBL1379374 0.76 TSHR (0.47) USP2MAPK1TSHRMAPTLMNA
SCHEMBL1383039 0.75 CHEK2 (0.46) USP2MAPK1TSHRMAPTLMNA
SCHEMBL1383960 0.75 ALDH1A1 (0.54) USP2MAPTLMNASMN1; SMN2MEN1
SCHEMBL1382078 0.73 TAAR1 (0.56) USP2MAPK1TSHRMAPTLMNA
SCHEMBL1381685 0.73 USP2 (0.52) USP2MAPK1TSHRMAPTLMNA
SCHEMBL24427668 0.73 KDM4E (0.54) SMN1; SMN2ALDH1A1PARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4805813-B2 2011-11-02 JP claimed
EP-1641765-A1 ARYL-HETEROAROMATIC PRODUCTS, COMPOSITIONS CONTAINING SAME AND USE THEREOF Aventis Pharma S.A. (FR) 2006-04-05 EP claimed
US-20050014765-A1 Aryl-heteroaromatic products, compositions comprising them and use AVENTIS PHARMA S.A. (FR) 2005-01-20 US claimed
WO-2004108685-A1 ARYL-HETEROAROMATIC PRODUCTS, COMPOSITIONS CONTAINING SAME AND USE THEREOF AVENTIS PHARMA S.A. (FR) 2004-12-16 WO claimed
EP-1641765-A1 ARYL-HETEROAROMATIC PRODUCTS, COMPOSITIONS CONTAINING SAME AND USE THEREOF Aventis Pharma S.A. (FR) 2006-04-05 EP disclosed
US-20050014765-A1 Aryl-heteroaromatic products, compositions comprising them and use AVENTIS PHARMA S.A. (FR) 2005-01-20 US disclosed
WO-2004108685-A1 ARYL-HETEROAROMATIC PRODUCTS, COMPOSITIONS CONTAINING SAME AND USE THEREOF AVENTIS PHARMA S.A. (FR) 2004-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014765-A1 Aryl-heteroaromatic products, compositions comprising them and use AHR, ARNT, MYC USP2 2195/4885MAPK1 4390/4885TSHR 3838/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.